Corporate AACE Partnership (CAP)

What is CAP?

Founded in 1993, the Corporate AACE Partnership (CAP) is a forum whose purpose is to develop and nurture an open dialogue between industry and our association to advance patient care. The mission of the CAP is to facilitate the improvement of endocrine patient care by working with industry in areas of mutual interest.

Current Partners

  • Abbott Diabetes Care

  • AbbVie

  • Amarin Pharma Inc.

  • Amgen

  • AstraZeneca

  • Bigfoot Biomedical

  • Boehringer Ingelheim Pharmaceuticals, Inc.

  • Chiasma

  • Corcept Therapeutics

  • Dexcom, Inc.

  • Health Monitor Network

  • Horizon Therapeutics

  • Insulet Corporation

  • Laboratory Corporation of America

  • Lexicon Pharmaceuticals

  • Lilly Diabetes

  • Mannkind Corporation

  • Medtronic, Inc

  • Merck-Pfizer Diabetes Collaboration

  • Novo Nordisk

  • Pfizer

  • PhRMA

  • Quest Diagnostics

  • Radius Health

  • Recordati Rare Diseases

  • Sandoz

  • Sanofi

  • Strongbridge Biophama

  • Takeda Pharmaceuticals U.S.A, Inc.

  • Vertex Pharmaceuticals

  • Xeris Pharmaceuticals

To learn more about the CAP or to request more details about joining the CAP, e-mail [email protected].

Request More Information